胸部恶性肿瘤免疫检查点抑制剂的神经系统并发症
本文综述免疫检查点抑制剂(ICI)在胸部恶性肿瘤中引起的神经系统免疫相关不良事件(irAEs)。神经系统受累相对罕见且高度异质,症状多在治疗前四个周期内出现,近三分之一患者预后不良。诊断需在排除转移、代谢或感染原因后怀疑,治疗依据临床严重程度选择停用ICI和/或免疫抑制治疗。
要点
- 神经系统irAEs相对罕见但高度异质,可累及中枢和周围神经系统。
- 症状多在ICI治疗前四个周期内出现,与ICI类别无关。
- 近三分之一患者预后不良,与患者特征、肿瘤类型和临床情境相关。
核心结论
- ICI治疗的胸部恶性肿瘤患者可出现高度异质的神经系统irAEs,早期识别和适当治疗对改善结局至关重要。
研究设计与样本
- 本文为综述,检索范围未在摘要中明确报告。
主要发现
- 神经系统irAEs包括伴或不伴神经特异性自身抗体的中枢和周围神经系统疾病、中枢神经系统血管炎、肉芽肿性和脱髓鞘性疾病。
- 症状多在治疗前四个周期内出现,且与所用ICI类别无关。
- 近三分之一患者预后不良,通常与患者临床特征(如年龄、合并全身不良事件)、肿瘤类型(如肺癌与其他)及特定临床情境相关。
关键数值与推荐
- 诊断应在ICI治疗中出现新发神经系统症状且不能由转移性疾病或其他代谢/感染性疾病解释时怀疑。
- 推荐治疗基于临床严重程度,包括停用ICI伴或不伴免疫抑制/免疫调节治疗;根据肿瘤状态可考虑替代方案(如初始肿瘤缓解者积极免疫抑制而不停用ICI)。
临床怎么用
- 对ICI治疗中出现新发神经系统症状的患者,应排除转移、代谢或感染原因后怀疑神经系统irAEs。
- 根据临床严重程度决定停用ICI及是否加用免疫抑制/免疫调节治疗,并结合肿瘤状态个体化调整。
局限性
- 本文为综述,摘要未报告系统检索策略、纳入研究数量及偏倚控制等局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibitors (ICIs) have transformed the prognosis of cancers previously considered lethal. The spectrum of therapeutic indications is rapidly expanding, including the vast majority of thoracic malignancies. By enhancing the immune responses against cancer, the ICI treatments lead to the development of immune-related adverse events (irAEs) that may affect any organ. Severity varies from mild to fatal clinical manifestations. Neurologic involvement is relatively rare and highly heterogeneous, including central and peripheral nervous system diseases associated with neural-specific autoantibodies or not, central nervous system vasculitis, and granulomatous and demyelinating disorders. Symptoms often manifest within the first four cycles of treatment and can develop regardless of the class of ICI used. An unfavorable outcome is found in up to one-third of patients and is generally associated with the patients' clinical characteristics (e.g., age, coexistence of systemic adverse events), cancer type (e.g., lung cancer versus other), and specific clinical setting (e.g., ICI treatment in patients with preexisting paraneoplastic neurologic autoimmunity, ICI rechallenge after a first neurologic irAE). Diagnosis should be suspected in patients with new-onset neurologic symptoms while on ICI treatment which are not explained by metastatic disease or other metabolic/infectious disorders. Recommended treatment is based on clinical severity and consists of ICI discontinuation with or without immunosuppressive/immunomodulatory therapy, although alternative approaches are reasonable depending on cancer status (e.g., aggressive immunosuppression without discontinuing ICI in patients with initial cancer response). Early recognition and appropriate treatment of these neurologic irAEs are crucial for improved patient outcomes and therapeutic planning.
引用
- Sechi E, Zekeridou A. Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies. J Thorac Oncol. 2020. PMID: 33188910. doi:10.1016/j.jtho.2020.11.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。